2238 Dicker, Adam P. - Thomas Jefferson University - Thomas Jefferson University
axd121

Adam P. Dicker, MD, PhD

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 503-0013 fax

Most Recent Peer-reviewed Publications

  1. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  2. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
  3. Study of Unrecovered Strain and Critical Stresses in One-Way Shape Memory Nitinol
  4. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905
  5. High dose rate brachytherapy boost for prostate cancer: A systematic review
  6. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
  7. A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect
  8. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
  9. Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial
  10. The quality frontier
  11. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
  12. A model to predict deflection of bevel-tipped active needle advancing in soft tissue
  13. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
  14. The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging
  15. Polyacrylamide phantom for self-actuating needle-tissue interaction studies
  16. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: Report of the american society for radiation oncology cancer biology/radiation biology task force, executive summary
  17. Radiation therapy and the immune system: Learning to live together
  18. Epidermal growth factor receptor mutation status and Rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation
  19. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
  20. Phase i trials involving radiation therapy, quantifying the risks
0